Novavax | NVAX - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
Adma Biologics USD 138.15M 50.52M 2026-03
Agenus USD 35M 32M 2026-03
AstraZeneca USD 7.56B 1.85B 2026-03
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
Cassava Sciences USD 86.57M 8.93M 2026-03
Geron USD 68.9M 10.54M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
MannKind USD 52.83M 22.05M 2026-03
Merck USD 5.33B 9.24B 2026-03
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Moderna USD 1.91B 687M 2026-03
Novartis USD 9.56B 2.9B 2025-09
Novavax USD 228.36M 12.27M 2026-03
Pfizer USD 1.7B 561M 2026-03
Sanofi EUR 7.66B 1.25B 2025-12
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
TG Therapeutics USD 442.21M 242.7M 2026-03